Erratum: Sphingosine Kinase-1 Enhances Resistance to Apoptosis through Activation of PI3K/Akt/NFκB Pathway in Human Non- small Cell Lung Cancer (Clin Cancer Res (2011) 17 (1839–1849) DOI: 10.1158/1078-0432.CCR-10-0720);Sphingosine kinase-1 enhances resistance to apoptosis through activation of PI3K/Akt/NF-κB pathway in human non-small cell lung cancer

Clinical Cancer Research

Volumn 17, Issue 7, 2011, Pages 1839-1849

  Song, Libing ^a   Xiong, Huaping ^a   Li, Jun ^a,b   Liao, Wenting ^a   Wang, Lan ^a   Wu, Jueheng ^a   Li, Mengfeng ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; LIPOCORTIN 5; LUCIFERASE; PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BCL XL; PROTEIN KINASE B; SPHINGOSINE 1 KINASE INHIBITOR; SPHINGOSINE KINASE 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL FEATURE; CONTROLLED STUDY; DRUG TARGETING; EMBEDDING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LUNG NON SMALL CELL CANCER; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING;

EID: 79953324725     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-22-0506     Document Type: Erratum

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Travis WD, Travis LB, Devesa SS. Lung cancer. Cancer 1995;75:191-202.
3. Jacques J, Hill DP, Shier KJ, Jindani A, Miller AB. (Appraisal of the World Health Organization classification of lung tumors. Can Med Assoc J 1980;122:897-901.
4. Yang P, Allen MS, Aubry MC, Wampfler JA, Marks RS, Edell ES, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-62.
5. Vallieres E. Role of adjuvant systemic therapy for stage I NSCLC. Thorac Surg Clin 2007;17:279-85. (Pubitemid 46862940)
6. Jeremic B, Milicic B, Dagovic A, Aleksandrovic J, Nikolic N, et al. Pretreatment clinical prognostic factors in patients with stage IV nonsmall cell lung cancer (NSCLC) treated with chemotherapy. J Cancer Res Clin Oncol 2003;129:114-22. (Pubitemid 36470093)
7. Kuwabara K, Matsuda S, Fushimi K, Anan M, Ishikawa KB, Horiguchi H, et al. Differences in practice patterns and costs between small cell and non-small cell lung cancer patients in Japan. Tohoku J Exp Med 2009;217:29-35.
8. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, et al. Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 2009;8:809-20.
9. Lee M J, Van Brocklyn JR, Thangada S, Liu CH, Hand AR, Menzeleev R, et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science 1998;279:1552-5. (Pubitemid 28217081)
10. Limaye V, Li X, Hahn C, Xia P, Berndt MC, Vadas MA, et al. Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1-dependent activation of PI-3K/Akt and regulation of Bcl-2 family members. Blood 2005;105:3169-77.
11. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 2006;1758:2016-26. (Pubitemid 44879368)
12. Xia P, Gamble JR, Wang L, Pitson SM, Moretti PA, Wattenberg BW, et al. An oncogenic role of sphingosine kinase. Curr Biol 2000;10:1527-30. (Pubitemid 32003646)
13. Olivera A, Kohama T, Edsall L, Nava V, Cuvillier O, Poulton S, et al. Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. J Cell Biol 1999;147:545-58.
14. Bonhoure E, Pchejetski D, Aouali N, Morjani H, Levade T, Kohama T, et al. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia 2006;20:95-102.
15. Bonhoure E, Lauret A, Barnes DJ, Martin C, Malavaud B, Kohama T, et al. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 2008;22:971-9. (Pubitemid 351689879)
16. Pchejetski D, Golzio M, Bonhoure E, Calvet C, Doumerc N, Garcia V, et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res 2005;65:11667-75. (Pubitemid 41821727)
17. Ibrahim L, Dominguez M, Yacoub M. Primary human adult lung epithelial cells in vitro: response to interferon-gamma and cytome-galovirus. Immunology 1993;79:119-24. (Pubitemid 23151203)
18. Hahn WC, Dessain SK, Brooks MW, King JE, Elenbaas B, Sabatini DM, et al. Enumeration of the simian virus 40 early region elements necessary for human cell transformation. Mol Cell Biol 2002;22:2111-23. (Pubitemid 34224619)
19. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7. (Pubitemid 27260107)
20. Li J, Zhang N, Song LB, Liao WT, Jiang LL, Gong LY, et al. Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res 2008; 14:3319-26.
21. Li J, Guan HY, Gong LY, Song LB, Zhang N, Wu J, et al. Clinical significance of sphingosine kinase-1 expression in human astrocytomas progression and overall patient survival. Clin Cancer Res 2008;14:6996-7003.
22. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 1999;9:601-4.
23. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
24. Dean EJ, Ranson M, Blackhall F, Holt SV, Dive C. (Novel therapeutic targets in lung cancer: Inhibitor of apoptosis proteins from laboratory to clinic. Cancer Treat Rev 2007;33: 203-12.
25. Bremer E, van Dam G, Kroesen BJ, de Leij L, Helfrich W. Targeted induction of apoptosis for cancer therapy: current progress and prospects. Trends Mol Med 2006;12:382-93. (Pubitemid 44164637)
26. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005;5:876-85. (Pubitemid 41746032)
27. Cuvillier O, Pirianov G, Kleuser B, Vanek PG, Coso OA, Gutkind S, et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1- phosphate. Nature 1996;381:800-3. (Pubitemid 26243122)
28. French KJ, Schrecengost RS, Lee BD, Zhuang Y, Smith SN, Eberly JL, et al. Discovery and evaluation of inhibitors of human sphingosine kinase. Cancer Res 2003;63:5962-9. (Pubitemid 37187498)
29. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999;36:99-114. (Pubitemid 29121684)
30. Lyseng-Williamson KA, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs 2005;65:2513-31. (Pubitemid 41697318)
31. Romashkova JA, Makarov SS. NF-kappaB is a target of AKT in antiapoptotic PDGF signalling. Nature 1999;401:86-90.
32. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 1996; 274:787-9.
33. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell 2004;6:203-8.